Status:
COMPLETED
A Long-term Study on the Side Effects of TRADIANCE in Japanese Patients With Type 2 Diabetes
Lead Sponsor:
Boehringer Ingelheim
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
Study objectives is to investigate the safety of long-term daily use of TRADIANCE® Combination Tablets AP and BP in Japanese patients with Type 2 Diabetes mellitus (T2DM) used in routine care.
Eligibility Criteria
Inclusion
- Japanese patients with Type 2 Diabetes mellitus (T2DM) who are prescribed with TRADIANCE® Combination Tablets AP or BP
- Patients who have never been treated with TRADIANCE® Combination Tablets AP or BP before enrolment
Exclusion
- None
Key Trial Info
Start Date :
January 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 27 2021
Estimated Enrollment :
1164 Patients enrolled
Trial Details
Trial ID
NCT03761797
Start Date
January 15 2019
End Date
April 27 2021
Last Update
January 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nippon Boehringer Ingelheim Co., Ltd
Tokyo, Japan, 1416017